StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $7.83 | $7.96 | +1.66% | 0.0M |
| 05-13 | $8.02 | $7.76 | -3.24% | 0.0M |
| 05-14 | $7.70 | $8.03 | +4.29% | 0.0M |
| 05-15 | $7.82 | $7.64 | -2.30% | 0.0M |
| 05-18 | $7.53 | $7.59 | +0.80% | 0.0M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Each factor shows MCRB's percentile within the scored universe — observational ranking, not a recommendation.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Metric | Q3 2026 (Est.) Expected 2026-08-04 | Q3 2025 2025-09-30 | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 | Q2 2022 2022-06-30 |
|---|---|---|---|---|---|
Revenue | $365.16K | $351.00K | $7.13M | $6.15M | $2.71M |
Operating Income | Not available | $-74.59M | $-179.91M | $-178.18M | $-119.08M |
Net Income | Not available | $21.03M | $-250.16M | $-181.36M | $-64.73M |
EPS (Diluted) | $-2.35 | $2.40 | $-2.31 | $-1.77 | $-1.32 |
Total Assets | Not available | $143.47M | $348.78M | $311.87M | $273.20M |
Total Liabilities | Not available | $99.78M | $338.00M | $244.28M | $250.14M |
Cash & Equivalents | Not available | $47.64M | $163.03M | $205.40M | $126.82M |
Free Cash Flow OCF − CapEx | Not available | $15.60M | $-238.64M | $-182.28M | $-121.45M |
Shares Outstanding | Not available | 8.76M | 125.22M | 124.41M | 92.31M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.